NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $1.09 +0.05 (+4.81%) Closing price 05/19/2025 04:00 PM EasternExtended Trading$1.09 0.00 (0.00%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Gossamer Bio Stock (NASDAQ:GOSS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Gossamer Bio alerts:Sign Up Key Stats Today's Range$1.03▼$1.1250-Day Range$0.78▼$1.4552-Week Range$0.50▼$1.55Volume1.66 million shsAverage Volume1.53 million shsMarket Capitalization$247.67 millionP/E RatioN/ADividend YieldN/APrice Target$7.75Consensus RatingBuy Company OverviewGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Read More… Gossamer Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreGOSS MarketRank™: Gossamer Bio scored higher than 77% of companies evaluated by MarketBeat, and ranked 232nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGossamer Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGossamer Bio has only been the subject of 3 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($0.28) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.43% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Gossamer Bio has recently increased by 9.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted4.43% of the outstanding shares of Gossamer Bio have been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Gossamer Bio has recently increased by 9.81%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.63 News SentimentGossamer Bio has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Gossamer Bio this week, compared to 2 articles on an average week.Search Interest25 people have searched for GOSS on MarketBeat in the last 30 days. This is an increase of 317% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GOSS Stock News HeadlinesGossamer Bio (NASDAQ:GOSS) Stock Price Expected to Rise, The Goldman Sachs Group Analyst SaysMay 18 at 2:53 AM | americanbankingnews.comEarnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecastsMay 17 at 10:52 PM | uk.investing.comDollar Collapse Warning: Protect Your Wealth NOWGlobal central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Americans are shifting savings out of traditional accounts to protect what they’ve earned. If you’re concerned about inflation, rising debt, or a falling dollar, this free Wealth Protection Kit includes three timely reports to help you prepare for what’s coming next.May 20, 2025 | Lear Capital (Ad)Cantor Fitzgerald maintains Overweight on Gossamer Bio stockMay 17 at 10:52 PM | uk.investing.comGOSSAMER BIO Earnings Results: $GOSS Reports Quarterly EarningsMay 17 at 10:52 PM | nasdaq.comGossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call TranscriptMay 17 at 5:51 PM | msn.comQ1 2025 Gossamer Bio Inc Earnings CallMay 16, 2025 | finance.yahoo.comGossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ...May 16, 2025 | finance.yahoo.comSee More Headlines GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $0.9046 at the beginning of 2025. Since then, GOSS shares have increased by 20.5% and is now trading at $1.09. View the best growth stocks for 2025 here. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. The business earned $9.89 million during the quarter, compared to analysts' expectations of $3.95 million. Read the conference call transcript. When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Top institutional investors of Gossamer Bio include Siren L.L.C. (2.29%), Monaco Asset Management SAM (2.13%), Alyeska Investment Group L.P. (1.83%) and Charles Schwab Investment Management Inc. (0.50%). Insiders that own company stock include Faheem Hasnain, Richard Aranda, Bryan Giraudo, Laura Carter and Caryn Peterson. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/15/2025Today5/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOSS CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$7.75 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+611.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,820,000.00 Net MarginsN/A Pretax Margin-64.89% Return on Equity-127.28% Return on Assets-22.12% Debt Debt-to-Equity Ratio3.64 Current Ratio6.74 Quick Ratio6.74 Sales & Book Value Annual Sales$114.70 million Price / Sales2.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book3.89Miscellaneous Outstanding Shares227,221,000Free Float215,274,000Market Cap$247.67 million OptionableOptionable Beta1.82 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:GOSS) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredAI Firm Enters America's Largest Medicaid MarketNew York's $95B system just approved a new AI healthcare platform. Here's what to know. A major shift in U....i2i Marketing Group, LLC | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Is Elon Musk’s New Device Getting so Popular?Many folks who’ve used it are raving online, calling it…“A game-changer”... an “amazing product”... and “amazi...Brownstone Research | SponsoredLenin was right all along… It’s not often you hear praise for a Bolshevik from a veteran investor… but Porter Stansberry says Lenin got o...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GOSS Stock Free GOSS Stock Alerts